CA3054758A1 - Mr1 restricted t cell receptors for cancer immunotherapy - Google Patents

Mr1 restricted t cell receptors for cancer immunotherapy Download PDF

Info

Publication number
CA3054758A1
CA3054758A1 CA3054758A CA3054758A CA3054758A1 CA 3054758 A1 CA3054758 A1 CA 3054758A1 CA 3054758 A CA3054758 A CA 3054758A CA 3054758 A CA3054758 A CA 3054758A CA 3054758 A1 CA3054758 A1 CA 3054758A1
Authority
CA
Canada
Prior art keywords
cell
cells
seq
cell receptor
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3054758A
Other languages
English (en)
French (fr)
Inventor
Gennaro De Libero
Marco LEPORE
Lucia Mori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Basel
Original Assignee
Universitaet Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Basel filed Critical Universitaet Basel
Publication of CA3054758A1 publication Critical patent/CA3054758A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3054758A 2017-03-07 2018-03-07 Mr1 restricted t cell receptors for cancer immunotherapy Pending CA3054758A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17159754 2017-03-07
EP17159754.5 2017-03-07
EP17179309.4 2017-07-03
EP17179309 2017-07-03
PCT/EP2018/055620 WO2018162563A1 (en) 2017-03-07 2018-03-07 Mr1 restricted t cell receptors for cancer immunotherapy

Publications (1)

Publication Number Publication Date
CA3054758A1 true CA3054758A1 (en) 2018-09-13

Family

ID=61563412

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3054758A Pending CA3054758A1 (en) 2017-03-07 2018-03-07 Mr1 restricted t cell receptors for cancer immunotherapy

Country Status (9)

Country Link
EP (2) EP4273233A3 (https=)
JP (2) JP7233103B2 (https=)
KR (1) KR20190126332A (https=)
CN (1) CN110462024B (https=)
AU (1) AU2018231405B2 (https=)
CA (1) CA3054758A1 (https=)
IL (1) IL268813A (https=)
WO (1) WO2018162563A1 (https=)
ZA (1) ZA201905579B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019525898A (ja) * 2016-06-10 2019-09-12 ガデタ・ベー・フェー ヒト白血球抗原拘束ガンマデルタｔ細胞受容体及びその使用方法
JP7486953B2 (ja) 2017-05-18 2024-05-20 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー 細胞標的化療法のための組成物および方法
GB201717578D0 (en) 2017-10-26 2017-12-13 Univ College Cardiff Consultants Ltd Novel T-cell receptor
CN112236447B (zh) * 2018-04-19 2023-10-20 得克萨斯州大学系统董事会 具有mage-b2特异性的t细胞受体及其用途
JP2022500038A (ja) * 2018-09-12 2022-01-04 ウニヴェルズィテート バーゼル 癌免疫療法用ｍｒ１制限ｔ細胞受容体
WO2020118094A1 (en) * 2018-12-06 2020-06-11 Guangdong Tcrcure Biopharma Technology Co., Ltd. Combinational tcr-t cell therapy targeting tumor antigens, tgf-beta, and immune checkpoints
CN113621070A (zh) 2020-05-06 2021-11-09 华夏英泰（北京）生物技术有限公司 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用
WO2022118043A1 (en) 2020-12-03 2022-06-09 Enara Bio Limited Novel protein-ligand complex
WO2022248881A1 (en) 2021-05-28 2022-12-01 Enara Bio Limited Novel protein-ligand complex
KR20230088292A (ko) * 2021-12-10 2023-06-19 주식회사 유틸렉스 MR1 제한적 Panck T 세포 및 이의 제조방법
WO2023148494A1 (en) * 2022-02-03 2023-08-10 University College Cardiff Consultants Limited Novel t-cell receptor
CN119587561B (zh) * 2024-12-09 2025-11-28 新乡医学院 THP在制备增强Vγ9Vδ2 T细胞抗肿瘤疗效的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2089229C (en) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
US7829289B2 (en) * 2002-05-14 2010-11-09 Institut National De La Sante Et De Recherche Medicale T cell subpopulation regulating gut immunity
JP6126804B2 (ja) * 2012-07-25 2017-05-10 国立大学法人富山大学 Ｔ細胞受容体のクローニング方法
WO2014160030A2 (en) * 2013-03-13 2014-10-02 Health Research, Inc. Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen
WO2015149130A1 (en) * 2014-04-01 2015-10-08 The University Of Queensland Immunological reagents and uses therefor

Also Published As

Publication number Publication date
EP4273233A2 (en) 2023-11-08
JP2020527036A (ja) 2020-09-03
CN110462024A (zh) 2019-11-15
JP7515209B2 (ja) 2024-07-12
WO2018162563A1 (en) 2018-09-13
KR20190126332A (ko) 2019-11-11
JP2023058659A (ja) 2023-04-25
AU2018231405B2 (en) 2024-02-08
IL268813A (en) 2019-10-31
ZA201905579B (en) 2024-08-28
EP3592839C0 (en) 2023-07-05
EP4273233A3 (en) 2023-11-15
EP3592839A1 (en) 2020-01-15
EP3592839B1 (en) 2023-07-05
AU2018231405A1 (en) 2019-09-26
CN110462024B (zh) 2024-08-09
JP7233103B2 (ja) 2023-03-06

Similar Documents

Publication Publication Date Title
EP3592839B1 (en) Mr1 restricted t cell receptors for cancer immunotherapy
US20250136940A1 (en) Nk cells with an increased antibody-dependent cellular toxicity (adcc) against tumors
ES2992909T3 (en) Methods and compositions for preparing genetically engineered cells
CN104780939B (zh) 用于细胞免疫治疗的方法和组合物
US11702459B2 (en) MR1 restricted T cell receptors for cancer immunotherapy
US20170313759A1 (en) Novel chimeric antigen receptors
US20220339271A1 (en) Mr1 restricted t cell receptors for cancer immunotherapy
US20200163992A1 (en) Nkt-cell subset for in vivo persistence and therapeutic activity and propagation of same
KR20170068598A (ko) 입양 세포 치료에서 복용을 위한 방법 및 조성물
KR20250048397A (ko) 메모리 기능을 갖는 t세포 또는 b세포의 증강제, 악성 종양 재발 억제제 및 t세포 또는 b세포에 메모리 기능을 유도하는 유도제
US11634498B2 (en) Chimeric antigen receptors and uses thereof
CN116096861A (zh) 过继性细胞转移的增强
CN111683971A (zh) 医药重组受体组成物及方法
US20240002465A1 (en) Mr1 restricted t cell receptors for cancer immunotherapy
TW202132326A (zh) Hla限制性hormad1 t細胞受體及其用途
CA3141210A1 (en) Modified nk-92 cells, and therapeutic and diagnostic uses thereof
US20230374104A1 (en) Methods and compositions comprising pd1 chimeric polypeptides
Stringhini Direct and Indirect Harnessing of Cytotoxic CD8+ T Lymphocytes for Cancer Therapy: Adoptive Cell Therapy Versus Immunocytokines
WO2025128822A1 (en) Lilrb3 modulators and methods of use thereof
WO2026003364A1 (en) Chimeric coreceptors
HK40015270B (zh) Hla限制性vgll1肽及其用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220921

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250226

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250226

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250226

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250507

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250908